(used in)
financing activities (101,768) 11,771
Effect of exchange rates on cash and
cash equivalents 654 311
Net increase (decrease) in cash and
cash equivalents 12,533 (197,513)
Cash and cash equivalents at
beginning of year 63,760 261,273
Cash and cash equivalents at end of
year 76,293 63,760
'/>"/>SOURCE Nektar Therapeutics Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related medicine news :1.
Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets2.
Nektar Therapeutics Announces Third Quarter 2007 Financial Results3.
Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York4.
Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia5.
Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City6.
Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets7.
Prime Therapeutics Receives TIPPS Certification8.
Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 129.
Transition Therapeutics Announces Fiscal 2007 Year End Financial Results10.
Lorus Therapeutics announces election of three new Directors and appoints a new Chairman11.
Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th